The objective of this study was to better understand the implications of the rate of prostate-speci®c antigen (PSA) changes in prostate carcinoma. We retrospectively calculated PSA doubling times prior to surgery in 62 patients with prostate carcinoma. The calculated values were compared with ®nal pathologic ®ndings and with rates of PSA failure after surgery. PSA values increased during the period of observation in 82.3% of the patients, whereas 17.7% had levels that remained stable. The median calculated PSA doubling time in those with increasing levels was 25.8 months, with doubling times 24 months observed in 37.1% of the patients. Stage pT3 disease was more common in patients with PSA doubling times of 36 months than in those with doubling times b 36 months (P 0.02). Biochemical failure was more common in patients with rapid PSA doubling times (P`0.01). The calculated PSA doubling time prior to radical surgery is signi®cantly associated with the ®nal pathologic ®ndings. Early PSA failure is more common in patients with rapid PSA doubling times prior to radical surgery. Prostate Cancer and Prostatic Diseases (2000) 3, 269±274.
Introduction
Effective methods are needed to distinguish clinically signi®cant prostate cancers requiring intervention from those that might possibly be better treated by expectant management. It has been suggested that calculated prostate speci®c antigen (PSA) doubling time predicts cancer aggressiveness. 1 ± 5 In contrast, several investigators failed to ®nd any signi®cant correlation between PSA doubling time and speci®c clinical parameters in patients followed expectantly. 6 ± 8 Whether PSA doubling time prior to therapy is of value for predicting the prognosis of individual patients thus remains controversial.
To better understand the relationship between PSA doubling time and cancer aggressiveness, we conducted a retrospective study to determine whether pre-radical prostatectomy PSA doubling time predicts pathological stage at radical prostatectomy or predicts PSA failure after surgery.
Hospital, four patients) between November 1991 and June 1999 and who had serial PSA measurements preoperatively. One additional patient (at Kurashiki), whose surgery was aborted owing to intraoperative discovery of gross tumor involvement outside the gland, was also included for analysis. This case, in which tumor invasion was con®rmed by biopsy, was treated and analyzed as having positive extracapsular extension, but excluded from other assessments such as seminal vesicle involvement, nodal involvement and margin status. His PSA never became undetectable postoperatively and androgen deprivation therapy was initiated.
All patients had had two or more preoperative PSA measurements covering an interval of at least 6 months. No patients received any form of preoperative hormonal ablation or chemotherapy.
PSA was measured at various laboratories using various techniques. These include Eiken polyclonal radioimmunoassay (Eiken, Tokyo, Japan), Dainapack IMx PSA assay (Dinabot, Tokyo, Japan), AxSYM PSA assay (Dinabot, Tokyo, Japan), Del®a PSA assay (Pharmacia and Upjohn Inc., Tokyo, Japan) and Lumipulse PSA assay (Fujirebio Inc., Tokyo, Japan). Eiken PSA assay was used to obtain initial PSA data in 12 cases. For uniformity, Eiken PSA data were inter-converted as follows: (IMx PSA) 1.39 6 (Eiken PSA) 7 1.02. 9 Results of other assays were not inter-converted, because they are considered virtually the same. 6,9 ± 11 After surgery, patients were evaluated at 3 ± 6 month intervals with a PSA measurement and digital rectal examination. Postoperative PSA values were considered elevated (PSA failure) if values of 0.1 ng/ml or greater were obtained on two consecutive visits 1 month apart for IMx, AxSYM and Lumipulse PSA assays, and 0.2 ng/ml or greater for the Del®a PSA assay.
Several different surgeons conducted radical retropubic prostatectomy at each institution. Histologic ®nd-ings were con®rmed by ultrasound-guided, six-sextant biopsy or by transurethral resection. Tumors were staged clinically according to the 1992 TNM classi®ca-tion. 12 All prostatectomy specimens but one were examined by the whole-organ step-section technique: the specimens were ®xed in 10% formalin and sectioned at 4 or 5 mm intervals in a plane perpendicular to the long axis of the gland, from the prostatic apex to the tip of the seminal vesicles, followed by staining with hematoxylin and eosin. One specimen was sectioned randomly.
All histology slides were examined and reviewed by a single, central pathologist (SK). Tumor grade and depth of capsular penetration were determined on the basis of criteria speci®ed previously. 13 Seminal vesicle involvement in the sections was searched for and assessed. Tumor area was measured using a planimeter. Allowance was made for prostate section thickness by multiplying the measured area by the actual thickness of a cut section. The volume of each tumor was determined in 60 patients by multiplying the measured volume by a shrinkage factor of 1.33.
For each patient, we calculated a linear regression of log PSA on time and computed the doubling time as log 2 divided by the slope. Prostatic volume was determined sonographically and calculated either as prostatic length 6 width 6 height 6 (p/6) (Kitasato, Kyoto) or as prostatic height 6 width 2 6 (p/6) (Kurashiki). No records of prostatic volume were available for the remaining institution.
The association of PSA doubling time with clinical stage, PSA level at diagnosis, specimen Gleason score, pathological ®ndings, PSA failure and risk-group assessment was studied. Risk-group strati®cation similar to that of D'Amico et al 14 was adopted; the only difference was the use of specimen rather than biopsy Gleason score.
Fisher's exact probability test, the chi-square test, the Mann ± Whitney U-test and Kruskal ± Wallis test were used for comparison of variables with P`0.05 considered signi®cant. Multivariate logistic regression analysis was conducted to assess the capacity of parameters for predicting pathological stage and biochemical failure with other variables controlled. These parameters included age, clinical stage, preoperative PSA, specimen tumor grade, PSA doubling time and risk-group classes.
Results

Patient characteristics and outcome of surgery
Median age of the 62 patients at radical prostatectomy was 67.0 y (range, 49 ± 78 y; mean, 65.7 y). The median follow-up period after radical surgery was 23.0 months (range, 1.0 ± 92.0 months; mean, 29.6 months). The diagnosis of prostate carcinoma was made by needle biopsy in 61 patients and at transurethral resection of the prostate gland in one patient. In 12 patients, the diagnosis was made at repeat biopsy following initially negative results. One patient was initially followed expectantly after diagnosis of prostate carcinoma, but later underwent radical surgery. Median preoperative serum PSA was 9.0 ng/ml (range, 1.8 ± 86.4 ng/ml; mean, 12.3 ng/ml). The median number of PSA recordings per patient was 4.0 (range, 2 ± 15 recordings) over a median period of 17.0 months (range, 6.0 ± 74.0 months) prior to radical prostatectomy. Nine patients had only two available PSA values. Seven patients (11.3%) had PSA levels b 20.0 ng/ml. The median gland volume was 32.9 cm 3 (range, 12.5 ± 64.4 cm 3 ; mean, 33.5 cm 3 ).
The 62 patients were classi®ed clinically as stage T 1b (one patient), T 1c (33 patients), T 2a (12 patients), T 2b (12 patients), T 2c (two patients), and T 3a (two patients). Specimen tumor grade was classi®ed as well differentiated (Gleason score 2 ± 4) and moderately differentiated (Gleason score 5 or 6) in ®ve (8.1%) and 22 (35.5%) patients, respectively. Thirty-®ve patients had poorly differentiated tumors, with Gleason scores of 7 in 31 patients (50.0%) and of 8 ± 10 in four patients (6.5%). Total tumor volume ranged from 0.1 to 17.8 cm 3 (mean, 2.8 cm 3 ; median, 1.6 cm 3 ).
Twenty-two patients (35.5%) had locally advanced disease on ®nal pathologic examination; extracapsular extension was seen in 20 patients (32.3%), seminal vesicle involvement in seven (11.3%), and microscopic nodal involvement in one (1.6%). Thirteen patients (21.0%) had positive surgical margins. To date, nine patients have experienced PSA failure at a median of 11.0 months following surgery (range, 0.0 ± 24.0). No clinical progression was reported.
Calculated PSA doubling times and clinicopathological parameters
Plots of serial PSA levels during the observation period are shown in Figure 1 . PSA values increased during the period of observation in 51 of the 62 patients (82.3%) ( Table 1) . Twenty-three patients (37.1%) had PSA doubling times of 2 y, whereas 11 patients (17.7%) had levels that remained stable. The proportions were almost the same when analysis was limited to the 54 patients with T 1 /T 2 disease and an initial PSA of 20.0 ng/ml. The median calculated PSA doubling time in patients with increasing levels was 25.8 months (range, 3.5 ± 228.8 months; mean, 39.7 months).
The relationships of PSA doubling time to clinical stage, PSA level at diagnosis, tumor grade, pathological ®ndings, risk group assessment, and PSA failure are outlined in Table 2 . Patients with T2/T3 cancers or seminal vesicle involvement exhibited more rapid PSA doubling times than did those without those characteristics (P`0.05). Though not statistically signi®cant, pathologically more advanced cancers tended to show increasing rather than stable PSA levels compared to con®ned disease (90.9% vs 67.5%, P 0.06). Those with PSA failure were more likely to have shorter PSA doubling times (15.1 months vs 30.5 months, P 0.01). No substantial difference in doubling time or frequency of stable PSA levels was noted among risk groups (P b 0.05). There was no association of PSA doubling time with PSA level at diagnosis, tumor grade, or extracapsular extension or surgical margin status (P b 0.05).
Calculated PSA doubling times and outcome of surgery
The relationships of the pathological ®ndings and of PSA failure to preoperative PSA doubling time are shown in Table 3 
Discussion
The optimum treatment for clinically localized prostate carcinoma has been controversial. 15 This is largely due to the paucity of data regarding the natural history of this disease and the resulting inability to predict the biological course of early stage prostate carcinoma.
The rate of change in PSA level has been suggested as a useful way to assess the status of prostate carcinoma followed expectantly. 1 ± 8,16 It has previously been shown that the median PSA doubling time of nonmetastatic prostate carcinoma is approximately 36 months (23 ± 56 months). 1 ± 8,16 However, only between 68% and 86% of such patients show increasing levels; no increase is seen in up to 30%. On the other hand, a short PSA doubling time (`24 months) is observed in 7 ± 47% of patients. It has been speculated that tumors with relatively stable or declining PSA levels may be in their linear phase of growth and may safely be followed for years without treatment. 6, 8, 17 , Conversely, tumors with rapidly increasing PSA levels may be in the exponential growth phase and thus signi®cant. The median calculated PSA doubling time in patients with increasing levels was 25.8 months in this study. Although this value is slightly lower than the one we previously calculated, 6 it has been claimed that tumor doubling time may be underestimated when the calculation is based on serial PSA changes. 6, 18 Nevertheless, there appear to be subpopulations of tumors with PSA levels that are, respectively, increasing and stable for a period of time prior to radical surgery.
Several investigators have suggested use of this parameter to predict treatment outcome prior to de®nitive therapy. 1,4,5 D'Amico and Hanks found that, following radiation therapy for prostate cancer, PSA doubling time was linearly correlated with the interval to clinical relapse after PSA failure. 5 They recommended observation rather than treatment for patients with PSA doubling times of ! 18 months, because the disease may not become clinically apparent during the patient's life time. Hanks et al considered PSA doubling time a predictor of biochemical disease-free survival following radiation therapy. 1 In their view, patients with pretreatment PSA doubling times`12 months have aggressive disease and should be candidates for multimodal therapy. On 4 However, the median follow-up after radical surgery was only 17.3 months in this study. With longer follow-up, the association of PSA doubling time with pathologic stage would presumably be translated into a correlation with PSA failure. The median follow-up period after radical prostatectomy in our study was slightly longer, 23.0 months, which may in part explain why we found an association between calculated PSA doubling times and PSA failure. It is of interest that all nine patients with PSA failure had preoperative PSA doubling times 36 months. Whether preoperative PSA doubling times can be used to drive clinical decision-making, especially in individual patients, still remains uncertain. Nevertheless, it appears that early PSA failure is more common in those with faster preoperative PSA doubling times.
Compared to pathologically more advanced cancers, organ-con®ned disease tended to show stable rather than increasing PSA levels (P 0.06). Stage pT 3 disease was more common in patients with fast PSA doubling times ( 36) months than in those with doubling times b 36 months (P 0.02), although the group with PSA doubling times b 36 months included ®ve of the 23 patients with pT3 disease (Table 3 ). This broad spectrum of distribution may in part account for the variable natural history of progression following radical prostatectomy. 19 Those with PSA failure were more likely to have shorter PSA doubling times (15.1 months vs 30.5 months, P 0.01). There was no association of PSA doubling time with PSA level at diagnosis, tumor grade, or risk-group assessment.
Our study is limited by its retrospective nature, by short follow-up time and by the small number of patients who had radical surgery. This may account for the inability of multivariate logistic regression analysis to detect any independent parameter for predicting pathological stage and biochemical failure. The variety of laboratories performing the PSA assays may be problematic as well. Use of the ®rst and last available PSA values to obtain PSA doubling time in some patients may also be a problem, but the values calculated by this method have been shown to correlate highly with those calculated by regression analysis. 16 A multi-institutional, prospective study is now underway. Further investigation is warranted. PSA, prostate-speci®c antigen; ECE, extracapsular extension; SVI, seminal vesicle involvement.
